Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics (NYSE: HAE) has announced a definitive agreement to acquire Cardiva Medical for $475 million upfront, plus $35 million contingent on sales growth. This strategic acquisition aims to enhance Haemonetics' offerings in interventional cardiology and electrophysiology markets. The deal is expected to generate $65-$75 million in revenue in its first fiscal year but may dilute adjusted net earnings by $0.15 to $0.20 in fiscal 2022. The acquisition is projected to break even on earnings by fiscal 2023 and deliver a 10% return on invested capital by year five.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2021 financial results on February 2, 2021, at 6:00 am EDT. Following this, a conference call for investors and analysts will occur at 8:00 am EDT on the same day to discuss the results. Access to the call is available via toll-free and international numbers, with a conference ID required. A live webcast will also be available on Haemonetics' investor relations website, with a replay accessible from February 2 to February 10, 2021.
Haemonetics Corporation (NYSE:HAE) has released its financial results for the second quarter of fiscal 2021, concluding on September 26, 2020. The earnings release and results tables are accessible on its Investor Relations website, along with a scheduled conference call for investors on November 4, 2020, at 8 a.m. EST. Key financial metrics and strategic updates are expected to be discussed during this call. Investors can also view the live webcast for detailed insights into the company's performance.
Haemonetics Corporation (NYSE: HAE) announced the upcoming release of its second quarter fiscal year 2021 financial results, scheduled for November 4, 2020, at 6:00 am EDT. Following the announcement, the Company will host a conference call at 8:00 am EDT to discuss the results and address investor inquiries. The call can be accessed via a toll-free number or through a live webcast on Haemonetics' investor relations website. A replay of the webcast will be available from November 4 to November 12, 2020.
On October 2, 2020, Haemonetics Corporation (NYSE: HAE) announced FDA 510(k) clearance for its NexSys PCS® system with Persona™ technology. This innovative system customizes plasma collection based on individual donor body composition. Results from the IMPACT study showed an 8.2% increase in collected plasma volume. Persona technology optimizes collection for donors based on BMI and hematocrit.
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on September 15, 2020, at 9:30 a.m. ET. The presentation will be accessible to the public via a live webcast and subsequent replay.
Haemonetics specializes in innovative hematology products aimed at enhancing patient care and reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) announced that results from its IMPACT study will be presented at the AABB Annual Meeting on October 4, 2020. The study, involving 3,443 donors and 23,137 plasma donations, tested a novel, personalized approach to plasma collection using the NexSys PCS® Plasma Collection System. The findings indicated an 8.2% increase in plasma volume collected per donation while maintaining a safe profile. This innovation addresses the growing demand for plasma-derived therapies, with the NexSys PCS device pending FDA approval.
Haemonetics Corporation (NYSE:HAE) announced its financial results for the first quarter of fiscal 2021, ending June 27, 2020. The detailed earnings release and results tables are now available on their Investor Relations website. The company will host a conference call for investors and analysts on August 4, 2020, at 8 a.m. EDT to discuss the results. Interested parties can access the call using a toll-free number or via a live webcast. For additional information, visit Haemonetics' official website.
Haemonetics Corporation (NYSE: HAE) announced the sale of its subsidiary Inlog Holdings France SAS to Abénex, a private equity firm, to enhance its focus on growth segments. This divestment includes software solutions like EdgeSuite™ and SapaNet™, which optimize operations in blood banks and hospital labs. The transaction is expected to close in Q3 2020, pending customary conditions. CEO Chris Simon emphasized this strategic move aligns with their Innovation Agenda, aiming to improve patient outcomes and maintain leadership in the hematology sector.
Haemonetics Corporation (NYSE: HAE) has announced that its 2020 Annual Meeting of Shareholders will be held virtually on July 21, 2020, at 8 a.m. Eastern Time. This decision is in response to the COVID-19 pandemic to ensure the health of participants. Only shareholders of record as of May 22, 2020 can attend the meeting by using a control number provided in their proxy materials. They are encouraged to vote prior to the meeting. Additional proxy materials have been filed with the SEC regarding voting and participation details.